Agilent Technologies Inc., a global analytical instrumentation development, life sciences and manufacturing company, has chosen to modernize and expand its existing Little Falls office and lab campus.
Agilent plans to invest more than $7 million to upgrade the functionality of its Little Falls R&D and applications development labs at the three-level, 354,000-square-foot Wilmington-area site. The company’s investment will go toward the complete redesign, demolition, construction, and outfitting of the existing laboratories.
“We are excited for Agilent Technologies’ expansion and modernization of their lab space, bringing new jobs to their facilities in New Castle County,” said Gov,. John Carney. “Delaware has a long tradition of expertise in the field of chemistry. This investment shows that Delaware remains a leader in innovative development.”
Agilent has been part of Delaware’s economy for more than 20 years after moving to Little Falls from Avondale, PA. Agilent is part of a cluster of testing technologies companies that have largely remained in Delaware.
Agilent currently employs more than 800 workers at Little Falls, west of Wilmington and additional employees at its manufacturing location in Newport. The Little Falls renovation and expansion will result in the company further expanding its workforce amid strong demand for its biopharmaceutical laboratory consumables.
“This another great example of investment in New Castle County where businesses have the access to talent and an incredible life sciences ecosystem,” said New Castle County Executive Matt Meyer. “We applaud Agilent Technologies on its commitment to New Castle County and the job creation that will result.”
Agilent officials presented to Delaware’s Council on Development Finance an application for a Jobs Performance Grant of $93,330 and a Capital Expenditures Grant of $210,000 from the Delaware Strategic Fund to supplement the company’s $7 million investment. Distribution of grants from the Delaware Strategic Fund are dependent on the company meeting commitments as outlined to the CDF, which reviewed and approved Agilent’s request for up to $303,330 in total grant funding.
“Agilent has a long and successful history in the State of Delaware, and this investment in our laboratories will enable world-class R&D for the fast-growing biopharma market, while expanding and supporting our Delaware-based team,” said John Gavenonis, vice president and general manager of Agilent’s Chemistries and Supplies Division. “Delaware is the right place for this R&D investment.”
